查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1948513

mRNA疫苗藥物開發服務市場（按服務類型、平台類型、遞送技術、治療領域、最終用戶和生產規模分類），全球預測（2026-2032年）

mRNA Vaccine Drugs Development Services Market by Service Type, Platform Type, Delivery Technology, Therapeutic Area, End User, Manufacturing Scale - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，mRNA 疫苗藥物開發服務市值將達到 38.4 億美元，到 2026 年將成長至 42.8 億美元，到 2032 年將達到 84.5 億美元，複合年成長率為 11.91%。

主要市場統計數據
基準年 2025 38.4億美元
預計年份：2026年 42.8億美元
預測年份：2032年 84.5億美元
複合年成長率 (%) 11.91%

建構現代mRNA疫苗研發和服務供應商之間合作所特有的綜合科學、營運和監管動態。

mRNA疫苗領域已從概念階段發展成為一個成熟的、服務主導的生態系統，科學創新、生產規模和監管專業知識在此融合，從而實現快速的治療方法開發。本導言重點闡述了支撐現代mRNA疫苗計畫的競爭動態和服務能力，並著重介紹了後續內容的核心主題。我們將重點闡述由研發團隊、合約研究機構和生產專家組成的整合網路如何在發現、臨床前、臨床和監管階段進行協作，以縮短研發週期並有效控制技術風險。

探索科學創新、監管變革和策略夥伴關係關係如何融合，重新定義mRNA疫苗研發管道。

科學突破、供應鏈重組和監管調整正共同推動mRNA疫苗從概念到臨床應用的變革性進程。構建體設計和序列最佳化的進步催生了效力更強、穩定性更高的候選疫苗，而脂質奈米顆粒製劑和新型遞送方式的同步改進則拓展了mRNA疫苗的治療範圍，使其從感染疾病擴展到腫瘤和罕見疾病領域。這些技術進步正在改變服務供應商的價值提案，要求他們提供更深入的轉化醫學專業知識和整合的工作流程，以支援複雜的專案。

了解2025年美國關稅對mRNA疫苗計畫的採購、供應鏈韌性和區域生產策略的影響

2025年美國關稅政策對全球關鍵原料、特殊耗材和某些外包服務的供應鏈造成了顯著影響。這些影響促使相關人員重新評估其脂質成分、核苷酸、專用設備等產品的籌資策略，並考慮供應商多元化和區域製造地的擴張。這導致採購風險重新分配，並加速了近岸外包計劃，以確保敏感的研發和生產流程的連續性。

了解多層細分（包括服務類型、平台變體、給藥方式、治療領域、最終用戶和生產規模）如何創造差異化的策略要務。

細分市場驅動mRNA疫苗服務生態系統的策略重點和營運設計。透過對服務類型、平台變體、遞送技術、治療領域、最終用戶和生產規模的深入分析，可以發現清晰的機會。按服務類型分類，該生態系統包括臨床開發、藥物發現服務、生產服務、臨床前服務和法規諮詢。臨床開發涵蓋I期、II期和III期臨床試驗，藥物發現服務包括體外評估、mRNA構建體設計和標靶分子鑑定。生產服務涵蓋商業化生產、製程開發和規模化生產，而臨床前服務則涉及動物模型研究和毒理學測試。法規諮詢著重於申請準備和提交支援。每個服務節點都需要獨特的能力和整合點，以支援不同開發階段之間的過渡。

影響美洲、歐洲、中東和非洲以及亞太地區mRNA疫苗計畫決策的比較優勢和營運權衡

區域趨勢顯著影響研發、生產和策略合作的位置，各主要區域的優勢和限制因素各不相同。在美洲，豐富的私人資本、成熟的新型療法監管經驗以及集中的生物製藥叢集，有利於快速轉化應用，並促進申辦方與專業服務供應商之間的密切合作。然而，該地區也面臨大規模mRNA生產能力的限制以及特殊原料供應鏈週期性緊張的問題，因此促使企業對國內生產能力進行戰略投資，並加強申辦方與區域合約研發生產機構（CDMO）之間的合作。

分析各公司如何透過平台投資、整合能力和可擴展的生產能力，在mRNA疫苗開發領域實現差異化並獲得專案級夥伴關係。

主要企業和服務供應商憑藉深厚的技術實力、貫穿整個研發階段的整合能力以及對可擴展生產基礎設施的投資脫穎而出。將藥物發現專長與製程開發和商業化生產能力相結合的公司，能夠為申辦方降低交接風險，並提供從早期候選藥物生成到最終上市的清晰路徑。同時，專業的受託研究機構（CRO）則透過其在先進製劑開發、適應性臨床試驗設計以及監管申報準備等方面的專長，持續創造價值。這些能力上的差異將影響合作夥伴的選擇，申辦方需要在全方位服務協議的優勢與和專業供應商合作的靈活性之間進行權衡。

為尋求加快mRNA疫苗研發進程、增強韌性並建立專案級夥伴關係關係的領導者提供以行動為導向的策略重點和能力投資

經營團隊應採取一系列策略行動，在科學雄心、營運韌性和監管前瞻性之間取得平衡。首先，投資於平台無關能力，實現環狀、非複製、自擴增mRNA構建體之間靈活的數據驅動切換，並結合多種遞送技術的專業知識，確保製劑選擇不會成為執行瓶頸。其次，優先與在藥物發現、臨床前、臨床和監管諮詢方面擁有綜合專業知識的供應商合作，以最大限度地減少營運交接環節，並加快風險緩解。第三，透過以下方式增強供應鏈韌性：實現關鍵前置作業時間來源多元化；就交貨週期長的物料協商靈活的長期合約；評估近岸外包和區域生產能力方案，以降低關稅和物流中斷的影響。

我們採用透明、嚴謹的多方法研究途徑，結合關鍵相關人員訪談、文件檢驗和定性三角驗證，為我們的策略結論提供支援。

為確保研究的深度和背景準確性，本研究綜合分析採用多管齊下的方法，結合了與關鍵相關人員的直接對話、有針對性的專家訪談以及二手文獻綜述。一級資訊來源包括與參與mRNA專案的研發總監、品質和生產總監、法規事務專家以及商業負責人進行的結構化對話，以獲取有關營運挑戰、夥伴關係偏好和技術採納模式的第一手資料。二手資訊來源包括同行評審文獻、監管指導文件和公司披露資訊，以檢驗技術趨勢並繪製服務供應商的能力分佈圖。

綜合分析表明，整合科學、營運和監管能力將決定哪些計畫和合作夥伴能夠成功推進mRNA疫苗研發計畫。

綜合證據表明，科學進步、營運能力和監管成熟度將決定mRNA疫苗候選產品從研發到臨床檢驗和商業化供應的進展速度。架構和遞送技術的進步正在拓展此方法的應用範圍，而能夠整合發現、開發、生產和監管工作的服務供應商可能在降低專案風險方面最為有效。同時，地緣政治和貿易趨勢日益凸顯供應鏈韌性和區域生產策略的重要性，迫使相關人員在效率和冗餘之間尋求平衡。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章 美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 mRNA疫苗藥物開發服務市場（依服務類型分類）

  • 臨床開發
    • 第一階段測試
    • 第二階段試驗
    • 第三階段試驗
  • 藥物發現支持服務
    • 體外評價
    • mRNA構建體設計
    • 標靶分子的鑑定
  • 製造服務
    • 商業生產
    • 製程開發
    • 擴大規模
  • 非臨床檢測服務
    • 動物模型研究
    • 毒理學測試
  • 監理諮詢
    • 準備申請文件
    • 應用程式支援

9. mRNA疫苗藥物開發服務市場（依平台類型分類）

  • 環狀mRNA
  • 非複製型mRNA
  • 自擴增mRNA
    • 非病毒性SARNA
    • 病毒來源的SARNA

第10章 依遞送技術分類的mRNA疫苗藥物開發服務市場

  • 脂質奈米顆粒
    • 陽離子脂質
    • 可電離脂質
    • 中性脂質
  • 胜肽
    • 細胞穿透胜肽
    • 目標胜肽
  • 聚合物
    • 陽離子聚合物
    • 樹狀聚合物
    • PEG聚合物

第11章 mRNA疫苗藥物開發服務市場（依治療領域分類）

  • 循環系統
  • 感染疾病
    • 細菌疫苗
    • 寄生蟲疫苗
    • 病毒疫苗
  • 腫瘤學
    • 新抗原疫苗
    • 個人化癌症疫苗
  • 罕見疾病

第12章 mRNA疫苗藥物開發服務市場（依最終用戶分類）

  • 生技公司
  • CRO（受託研究機構）
    • 全方位CRO服務
    • 專業服務首席營收官
  • 製藥公司

第13章 mRNA疫苗藥物開發服務市場（依生產規模分類）

  • 商業規模
  • 實驗室規模
  • 中試規模

第14章 mRNA疫苗藥物開發服務市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 mRNA疫苗藥物開發服務市場（按組別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國mRNA疫苗藥物研發服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國mRNA疫苗藥物開發服務市場

第18章：中國mRNA疫苗藥物研發服務市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abogen Biosciences Co., Ltd.
  • Arcturus Therapeutics Holdings Inc.
  • AstraZeneca plc
  • BioNTech SE
  • Chengdu Walvax BIoTechnology Co., Ltd.
  • CRISPR Therapeutics AG
  • CureVac NV
  • Daiichi Sankyo Company, Limited
  • eTheRNA Immunotherapies NV
  • Ethris GmbH
  • Genevant Sciences Corporation
  • Gennova Biopharmaceuticals Ltd.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Providence Therapeutics Holdings Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Siam Bioscience Co., Ltd.
  • Stemirna Therapeutics Co., Ltd.
  • Translate Bio, Inc.
  • TriLink BioTechnologies, LLC
  • Zydus Cadila
Product Code: MRR-4F7A6D4FB7DA

The mRNA Vaccine Drugs Development Services Market was valued at USD 3.84 billion in 2025 and is projected to grow to USD 4.28 billion in 2026, with a CAGR of 11.91%, reaching USD 8.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.84 billion
Estimated Year [2026] USD 4.28 billion
Forecast Year [2032] USD 8.45 billion
CAGR (%) 11.91%

Framing the integrated scientific, operational, and regulatory dynamics that now define modern mRNA vaccine development and service provider collaboration

The mRNA vaccine landscape has transitioned from conceptual promise to a mature, service-driven ecosystem where scientific innovation, manufacturing scale, and regulatory acumen converge to enable rapid therapeutic development. This introduction frames the core themes that follow by clarifying the competitive dynamics and service capabilities that underpin contemporary mRNA vaccine programs. It emphasizes how integrated networks of discovery teams, contract research organizations, and manufacturing specialists now collaborate across discovery, preclinical, clinical, and regulatory stages to compress timelines while managing technical risk.

Industry actors are navigating a complex array of scientific choices, from platform selection to delivery modalities, which in turn shape vendor selection and partnership models. These choices directly affect project architecture, cost structures, and regulatory interactions. Consequently, program leaders must balance platform innovation with pragmatic decisions about delivery technology, process development, and scale readiness. This introduction sets the stage for a deeper discussion of transformative shifts, tariff-related disruptions, segmentation-driven priorities, regional differentiators, and the competitive plays that will influence how organizations design and execute mRNA vaccine programs over the coming years.

Identifying the confluence of scientific innovation, regulatory evolution, and strategic partnerships that are redefining development pathways for mRNA vaccines

Scientific breakthroughs, supply chain reconfiguration, and regulatory adaptation are jointly propelling a transformational shift in how mRNA vaccines progress from concept to clinic. Advances in construct design and sequence optimization are enabling more potent and stable candidates, while parallel improvements in lipid nanoparticle formulations and alternative delivery modalities are broadening the therapeutic scope beyond infectious disease into oncology and rare diseases. These technical advances are changing the value proposition of service providers, who must now offer deeper translational expertise and integrated workflows to support complex programs.

Regulatory frameworks are simultaneously evolving to accommodate novel modalities and accelerated pathways, which places a premium on early and continuous regulatory engagement. As a result, service firms that combine dossier preparation, clinical development know-how, and manufacturing scale-up experience are increasingly preferred partners. At the same time, commercial imperatives are driving consolidation and strategic partnerships between biotechnology firms, specialized CROs, and manufacturers to de-risk timelines and secure capacity. These converging shifts underscore a landscape in which agility, cross-disciplinary capabilities, and demonstrable regulatory familiarity determine which providers will lead in enabling next-generation mRNA vaccine programs.

Understanding how the 2025 United States tariff measures have reshaped sourcing, supply chain resilience, and regional manufacturing strategies for mRNA vaccine programs

The imposition of tariffs by the United States in 2025 has introduced measurable friction into global supply chains for critical raw materials, specialized consumables, and certain outsourced services. This friction has prompted stakeholders to reassess sourcing strategies for inputs such as lipid components, nucleotides, and specialized equipment, leading to supplier diversification and increased consideration of regional manufacturing footprints. The cumulative effect has been a redistribution of procurement risk and an acceleration of nearshoring initiatives aimed at preserving continuity for sensitive development and manufacturing workflows.

Operationally, programs with tightly integrated international supply chains have experienced longer lead times for specific reagents and components, prompting sponsors to build redundant suppliers and to re-evaluate inventory strategies. At the strategic level, service providers with vertically integrated manufacturing capabilities or strong regional bases have gained competitive advantage as sponsors prioritize resilience and rapid responsiveness. Furthermore, tariffs have sharpened negotiations around contractual terms for long-lead items, incentivized multi-year supply agreements, and encouraged collaborative investments in regional capacity to minimize exposure to future tariff volatility. Looking forward, managing tariff-induced complexity will require a synthesis of procurement agility, contractual innovation, and proactive regional capacity planning.

Revealing how layered segmentation across service types, platform variants, delivery modalities, therapeutic focuses, end users, and manufacturing scales creates differentiated strategic imperatives

Segmentation drives both strategic focus and operational design across the mRNA vaccine services ecosystem, and a granular view of service types, platform variants, delivery technologies, therapeutic areas, end users, and manufacturing scales reveals distinct opportunity vectors. Based on Service Type, the landscape encompasses Clinical Development, Discovery Services, Manufacturing Services, Preclinical Services, and Regulatory Consulting, with Clinical Development spanning Phase I, Phase II, and Phase III trials, Discovery Services including in vitro evaluation, mRNA construct design, and target identification, Manufacturing Services covering commercial manufacturing, process development, and scale up, Preclinical Services addressing animal model studies and toxicology studies, and Regulatory Consulting focused on dossier preparation and submission support. Each service node requires unique capabilities and integration points to support transition across development stages.

Based on Platform Type, choices between circular mRNA, nonreplicating mRNA, and self-amplifying mRNA-where self-amplifying variants further divide into nonviral and viral-derived approaches-inform potency expectations, dosing strategies, and regulatory engagement. Based on Delivery Technology, options span lipid nanoparticle, peptide, and polymer approaches, with lipid nanoparticle chemistry differentiated into cationic, ionizable, and neutral lipids, peptide strategies split into cell-penetrating and targeting peptides, and polymer choices including cationic polymers, dendrimers, and PEGylated polymers; these delivery decisions directly affect formulation complexity and manufacturing constraints. Based on Therapeutic Area, programs focus on cardiovascular, infectious disease, oncology, and rare disease indications, with infectious disease further segmented into bacterial, parasitic, and viral vaccines, and oncology including neoantigen and personalized cancer vaccine strategies, each imposing different clinical and regulatory pathways. Based on End User, the ecosystem serves biotechnology firms, contract research organizations, and pharmaceutical companies, with CROs distinguishing between full-service and specialized providers. Based on Manufacturing Scale, efforts are organized around commercial, laboratory, and pilot-scale operations, and scale decisions influence facility design, quality systems, and technology transfer timelines. Synthesizing these segmentation dimensions highlights where providers should invest to meet sponsor needs, and where sponsors should prioritize partner capabilities when assembling development and manufacturing strategies.

Comparative regional strengths and operational tradeoffs across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape mRNA vaccine program decisions

Regional dynamics materially influence where sponsors choose to locate development, manufacturing, and strategic partnerships, and each major geography presents distinct strengths and constraints. In the Americas, private capital depth, established regulatory experience with novel modalities, and concentrated biopharma clusters support rapid translational activity and enable close collaboration between sponsors and specialized service providers. However, the region also contends with capacity constraints for large-scale mRNA manufacturing and periodic supply chain pinch points for specialized inputs, which has led to strategic investments in domestic capacity and stronger ties between sponsors and regional CDMOs.

In Europe, Middle East & Africa, a mature regulatory environment combined with a robust contract research and manufacturing base supports high-quality development work and innovative public-private partnerships. The region's strength in advanced bioprocessing and formulation development positions it as a critical hub for process optimization and clinical-phase manufacturing, while regulatory coordination across jurisdictions remains an area where early planning pays dividends. In Asia-Pacific, rapidly expanding manufacturing capacity, competitive cost structures, and strong talent pools for process development and scale-up make the region attractive for both pilot-scale and commercial-scale production. At the same time, sponsors must account for variability in regulatory pathways and intellectual property frameworks across countries, which necessitates targeted regional strategies. Across all regions, successful programs balance local operational advantages with global supply chain resilience to ensure continuity and regulatory compliance.

Profiling how companies are differentiating through platform investments, integrated capabilities, and scalable manufacturing to capture program-level partnerships in mRNA vaccine development

Leading companies and service providers are differentiating through depth of technical capability, integration across development stages, and investments in scalable manufacturing infrastructure. Firms that combine discovery expertise with process development and commercial manufacturing capacity offer sponsors a reduced handoff risk and a clearer route from early candidate generation to market supply. Meanwhile, specialized CROs continue to command value through niche capabilities such as advanced formulation development, adaptive clinical trial design, and regulatory dossier craftsmanship. These capability distinctions inform partner selection, where sponsors weigh the benefits of full-service relationships against the flexibility of working with specialized vendors.

Competitive positioning is also influenced by strategic investments in platform technologies and delivery systems. Companies that have established robust platforms-whether in circular mRNA, self-amplifying approaches, or advanced lipid nanoparticle chemistries-are better positioned to support rapid iteration and platform-driven pipelines. Additionally, business models that offer flexible manufacturing scale options, from pilot to commercial, and that can navigate complex quality and regulatory requirements are increasingly attractive. Partnerships, mergers, and targeted capacity expansions are common moves among incumbents and new entrants alike, reflecting a market where technical credibility and operational scale together determine which firms will capture sustained program-level engagements.

Action-oriented strategic priorities and capability investments for leaders aiming to accelerate development timelines, strengthen resilience, and secure program-level partnerships in mRNA vaccine initiatives

Executives should pursue a coordinated set of strategic actions that balance scientific ambition with operational resilience and regulatory foresight. First, invest in platform-agnostic capabilities that allow programs to pivot among circular, nonreplicating, and self-amplifying mRNA constructs as data dictates, and pair those capabilities with expertise in multiple delivery technologies so formulation choices do not become executional bottlenecks. Second, prioritize partnerships with providers that demonstrate integrated expertise across discovery, preclinical, clinical, and regulatory consulting to minimize handoffs and accelerate de-risking. Third, enhance supply chain resilience by diversifying suppliers for critical reagents, negotiating flexible long-term contracts for long-lead items, and evaluating nearshoring or regional capacity options to mitigate tariff and logistics shocks.

Moreover, organizations should build regulatory engagement into program architecture early and continuously, leveraging dossier preparation and submission support to streamline interactions with authorities. Invest in scalable process development and pilot facilities that are designed for rapid tech transfer, and consider strategic investments or partnerships to secure commercial manufacturing capacity. Finally, align commercial and clinical strategies to therapeutic area realities, recognizing that oncology and personalized vaccine efforts require distinct clinical and manufacturing approaches compared with infectious disease campaigns. Executing these recommendations will strengthen program resilience and competitive positioning across evolving development landscapes.

Transparent and rigorous multi-method research approach combining primary stakeholder interviews, documentary validation, and qualitative triangulation to underpin strategic conclusions

This research synthesis is grounded in a multi-method approach that integrates primary stakeholder engagement, targeted expert interviews, and secondary literature review to ensure both depth and contextual accuracy. Primary inputs included structured conversations with development leaders, quality and manufacturing heads, regulatory affairs specialists, and commercial strategists involved in mRNA programs, which provided first-hand perspectives on operational challenges, partnership preferences, and technology adoption patterns. Secondary inputs drew on peer-reviewed literature, regulatory guidance documents, and company disclosures to validate technical trends and to map capability footprints across service providers.

Data were triangulated through cross-validation across interview responses and documentary evidence, and qualitative coding techniques were applied to identify recurring themes such as delivery technology preferences, platform trade-offs, and regional capacity dynamics. The analysis emphasizes robustness by acknowledging inherent uncertainties and by focusing on directional insights and strategic implications rather than quantitative forecasts. Where interpretation risk existed, alternative scenarios and sensitivity considerations were used to present balanced conclusions that will be relevant to decision-makers navigating development, manufacturing, and regulatory pathways for mRNA vaccine programs.

Concluding synthesis highlighting how integrated scientific, operational, and regulatory capabilities will determine which programs and partners succeed in advancing mRNA vaccine initiatives

The collective evidence points to an ecosystem in which scientific progress, operational capability, and regulatory sophistication will determine the pace at which mRNA vaccine candidates advance to clinical validation and commercial supply. Technical advances in construct design and delivery are expanding the modality's applicability, while service providers that integrate discovery, development, manufacturing, and regulatory counsel will be most effective at reducing program risk. At the same time, geopolitical and trade developments have heightened the importance of supply chain resilience and regional manufacturing strategy, prompting stakeholders to balance efficiency with redundancy.

Ultimately, organizations that combine platform flexibility, delivery expertise, and early regulatory engagement will be best positioned to capitalize on emerging opportunities. Strategic investments in scalable process development, secure supply chains, and partnerships with integrated service providers will accelerate program timelines and mitigate exposure to external shocks. The conclusion underscores that success in mRNA vaccine development is increasingly a function of coordinated capabilities across scientific, operational, and regulatory domains rather than the strength of any single element.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. mRNA Vaccine Drugs Development Services Market, by Service Type

  • 8.1. Clinical Development
    • 8.1.1. Phase I Trials
    • 8.1.2. Phase II Trials
    • 8.1.3. Phase III Trials
  • 8.2. Discovery Services
    • 8.2.1. In Vitro Evaluation
    • 8.2.2. Mrna Construct Design
    • 8.2.3. Target Identification
  • 8.3. Manufacturing Services
    • 8.3.1. Commercial Manufacturing
    • 8.3.2. Process Development
    • 8.3.3. Scale Up
  • 8.4. Preclinical Services
    • 8.4.1. Animal Model Studies
    • 8.4.2. Toxicology Studies
  • 8.5. Regulatory Consulting
    • 8.5.1. Dossier Preparation
    • 8.5.2. Submission Support

9. mRNA Vaccine Drugs Development Services Market, by Platform Type

  • 9.1. Circular Mrna
  • 9.2. Nonreplicating Mrna
  • 9.3. Self Amplifiying Mrna
    • 9.3.1. Nonviral Sarna
    • 9.3.2. Viral Derived Sarna

10. mRNA Vaccine Drugs Development Services Market, by Delivery Technology

  • 10.1. Lipid Nanoparticle
    • 10.1.1. Cationic Lipid
    • 10.1.2. Ionizable Lipid
    • 10.1.3. Neutral Lipid
  • 10.2. Peptide
    • 10.2.1. Cell Penetrating Peptides
    • 10.2.2. Targeting Peptides
  • 10.3. Polymer
    • 10.3.1. Cationic Polymer
    • 10.3.2. Dendrimers
    • 10.3.3. Peg Polymer

11. mRNA Vaccine Drugs Development Services Market, by Therapeutic Area

  • 11.1. Cardiovascular
  • 11.2. Infectious Disease
    • 11.2.1. Bacterial Vaccines
    • 11.2.2. Parasitic Vaccines
    • 11.2.3. Viral Vaccines
  • 11.3. Oncology
    • 11.3.1. Neoantigen Vaccines
    • 11.3.2. Personalized Cancer Vaccines
  • 11.4. Rare Disease

12. mRNA Vaccine Drugs Development Services Market, by End User

  • 12.1. Biotechnology Firms
  • 12.2. Contract Research Organizations
    • 12.2.1. Full Service CROS
    • 12.2.2. Specialized Service CROS
  • 12.3. Pharmaceutical Companies

13. mRNA Vaccine Drugs Development Services Market, by Manufacturing Scale

  • 13.1. Commercial Scale
  • 13.2. Laboratory Scale
  • 13.3. Pilot Scale

14. mRNA Vaccine Drugs Development Services Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. mRNA Vaccine Drugs Development Services Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. mRNA Vaccine Drugs Development Services Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States mRNA Vaccine Drugs Development Services Market

18. China mRNA Vaccine Drugs Development Services Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abogen Biosciences Co., Ltd.
  • 19.6. Arcturus Therapeutics Holdings Inc.
  • 19.7. AstraZeneca plc
  • 19.8. BioNTech SE
  • 19.9. Chengdu Walvax Biotechnology Co., Ltd.
  • 19.10. CRISPR Therapeutics AG
  • 19.11. CureVac N.V.
  • 19.12. Daiichi Sankyo Company, Limited
  • 19.13. eTheRNA Immunotherapies NV
  • 19.14. Ethris GmbH
  • 19.15. Genevant Sciences Corporation
  • 19.16. Gennova Biopharmaceuticals Ltd.
  • 19.17. GlaxoSmithKline plc
  • 19.18. Merck & Co., Inc.
  • 19.19. Moderna, Inc.
  • 19.20. Novavax, Inc.
  • 19.21. Pfizer Inc.
  • 19.22. Providence Therapeutics Holdings Inc.
  • 19.23. Regeneron Pharmaceuticals, Inc.
  • 19.24. Sanofi S.A.
  • 19.25. Siam Bioscience Co., Ltd.
  • 19.26. Stemirna Therapeutics Co., Ltd.
  • 19.27. Translate Bio, Inc.
  • 19.28. TriLink BioTechnologies, LLC
  • 19.29. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE I TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE I TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE I TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE II TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE II TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE II TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE III TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE III TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHASE III TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY IN VITRO EVALUATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY IN VITRO EVALUATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY IN VITRO EVALUATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MRNA CONSTRUCT DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MRNA CONSTRUCT DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MRNA CONSTRUCT DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SCALE UP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SCALE UP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SCALE UP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ANIMAL MODEL STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ANIMAL MODEL STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ANIMAL MODEL STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DOSSIER PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DOSSIER PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DOSSIER PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SUBMISSION SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SUBMISSION SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SUBMISSION SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CIRCULAR MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CIRCULAR MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CIRCULAR MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NONREPLICATING MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NONREPLICATING MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NONREPLICATING MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NONVIRAL SARNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NONVIRAL SARNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NONVIRAL SARNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY VIRAL DERIVED SARNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY VIRAL DERIVED SARNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY VIRAL DERIVED SARNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CATIONIC LIPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CATIONIC LIPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CATIONIC LIPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY IONIZABLE LIPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY IONIZABLE LIPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY IONIZABLE LIPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NEUTRAL LIPID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NEUTRAL LIPID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NEUTRAL LIPID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TARGETING PEPTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TARGETING PEPTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY TARGETING PEPTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CATIONIC POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CATIONIC POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CATIONIC POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DENDRIMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DENDRIMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEG POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEG POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEG POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY BACTERIAL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY BACTERIAL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY BACTERIAL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PARASITIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PARASITIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PARASITIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY VIRAL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY VIRAL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY VIRAL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NEOANTIGEN VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NEOANTIGEN VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY NEOANTIGEN VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PERSONALIZED CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PERSONALIZED CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PERSONALIZED CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY RARE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY RARE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY RARE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY FULL SERVICE CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY FULL SERVICE CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY FULL SERVICE CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SPECIALIZED SERVICE CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SPECIALIZED SERVICE CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SPECIALIZED SERVICE CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LABORATORY SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LABORATORY SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LABORATORY SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PILOT SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PILOT SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 187. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 188. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 189. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2032 (USD MILLION)
  • TABLE 204. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 206. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY POLYMER, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DISCOVERY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY CONSULTING, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PLATFORM TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY SELF AMPLIFIYING MRNA, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY DELIVERY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY LIPID NANOPARTICLE, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE MRNA VACCINE DRUGS DEVELOPMENT SERVICES MARKET SIZE, BY PEPTIDE, 2018-2032 (USD MILLION)

TABLE 2